Monthly Archives: August 2013

Behind the China Bribery Scandals

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China. Big names were engulfed in the scandal, including GSK, AstraZeneca, Sanofi, Novartis, Eli Lilly, Novo Nordisk and UCB amongst others. Last month, four GSK executives were put under investigation for allegedly paying up to […]
Posted in Emerging Markets, Global, Guest Blog | Tagged , , , , , , , , , | Leave a comment

The Sunshine Act Makes for Gloomy Sales Reps

On Café Pharma message boards, the drug industry’s online water cooler, anonymous sales reps are sounding off on the Physician Payment Sunshine Act and its implications for their battered profession. Here’s a selection from a thread that PharmExec came across, edited for spelling, punctuation, and coherence:
Posted in Advertising, compliance, Marketing, Medical Education, Regulatory, Sales, social media | Tagged , , , | 2 Comments

How to Win in the Diabetes Space

Novo Nordisk’s SVP of national diabetes sales speaks with PharmExec about a new field force technology initiative, implications of the Sunshine Act, and why Victoza sales won’t slow down anytime soon. At a time when meaningful growth at most big pharma companies is happening in emerging markets – and nowhere else – Novo’s 2Q earnings […]
Posted in compliance, FDA, healthcare, leadership, patient education, People, Sales, Strategy, Technology | Tagged , , , , , , , , , | 5 Comments

Specialty Drugs: A Tempting Target, But What to Do?

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life-altering diseases.  The financial and reputational stakes for players in this hotly contested commercial space are high, compounded by a startling lack of awareness of the incentives that drive specific […]
Posted in Biotech, Market Access, Meetings, pricing, Strategy | Tagged , , , , , , , , | Leave a comment
  • Categories

  • Meta